2022 - RAS Dialogue

KRAS G12C-mediated immunosuppression is released by KRAS G12C inhibitors

KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours

November 14, 2022, by Jesse Boumelha, Edurne Mugarza, Sophie de Carné Trécesson, Febe van Maldegem, Miriam Molina and Julian Downward Francis Crick Institute, London

The use of Molecular Docking as a ligand discovery tool; Can machine learning help the pursuit for ligands?

July 6, 2022, by Trent E. Balius and Megan Rigby

Ribbon diagram of the NF1 protein in an occluded conformation

Could CryoEM structures of neurofibromin lead the way to better therapeutic approaches for Neurofibromatosis type 1?

May 18, 2022, by Dom Esposito

Top-Down Proteomics Reveals the KRAS Proteoform Landscape in Colorectal Cancer

March 24, 2022

Measuring PTM differences across RAS isoforms and mutants is quite the challenge. Here, the authors discuss how they used top-down proteomics to uncover a diverse RAS proteoform landscape across cancer cell lines and tumor samples.

Sin1: a novel RAS effector with isoform specificity

February 22, 2022

Sin1, a member of the mTORC2 complex, is found to interact preferentially with KRAS4A via an atypical RAS binding domain. This interaction is shown to be dispensable for mTORC2 activity.

2022 - RAS Dialogue

Archive